In a pioneering move set to transform cancer diagnostics in India, Dr. Lal PathLabs (DLPL) has become the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases. This cutting-edge technology, validated in
Dr. Lal PathLabs Limited (“DLPL”), one of India’s most trusted diagnostic chains, has expanded its genomics capabilities by adding Illumina’s NovaSeq™ X Series to its dedicated genomics division, Genevolve. With the integration of Illumina’s latest technology, DLPL can now deliver faster and more accurate genomic
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
